Hummelstown, PA-based startup MacuLogix has raised $5 million to back its FDA-cleared diagnostic test for dark adaptation function disorders, which include age-related macular degeneration and retinitis pigmentosa. The loss of the ability of the eye to adapt to the dark is a very early indicator of those kinds of diseases.
Reps. Renee Ellmers (R-NC) and Debbie Wasserman Schultz (D-FL) submitted a bill that would overrule a recent U.S. Preventive Services Task Force recommendation against insurance coverage for routine mammograms for women aged 40 to 49 for two years.
As the med tech industry homes in on rapid, point-of-care diagnostics geared toward low-income countries, an Indian diagnostics company is developing a "lab-on-cartridge" device that uses inexpensive technology to quickly scan for a host of diseases and conditions.
GE Healthcare is betting that a more than $1 billion investment over 5 years to train more than 2 million global healthcare providers will pay off. In developed economies, it's looking to ingratiate itself by offering options for improving efficiency as the demand for value-based healthcare looms, while in emerging economies it hopes to establish itself firmly as more people are able to receive basic healthcare.
Diagnostics are about to be available anywhere the patient is with a new device from Cepheid that it says is the first point-of-care diagnostic device intended for such a broadly defined area of use. The company is unveiling the device at this week's American Association for Clinical Chemistry meeting in Atlanta, GA.
In a continuing effort dubbed the Head Health Initiative,the NFL and partner GE have made awards of $500,000 to the 6 winners of the first of four planned research challenges. This is in addition to $300,000 in grants that it gave to 16 winners in the first round. Between them, they may be awarded a total of up to $10 million.
Despite strong contributions from fingerstick-free blood glucose monitor Freestyle Libre and mitral valve repair device MitraClip--medical devices remained the worst performing business for Abbott Laboratories last quarter as sales climbed 3.1% on an operational basis to $1.3 billion.
The U.K.'s University of Cambridge touted a study which suggests that its swallowable "pill on a string" has utility because it scrapes off numerous cancer cells from the esophagus as it is withdrawn.
As fetal-ultrasound procedures continue to increase in the U.S., medical experts are cautioning against running frequent scans with the devices.
European researchers from several companies and academic centers are working toward creating a photonic laser-based device that would enable the diagnosis and monitoring of cancer patients in the physician's office. The four-year project is funded via Horizon 2020, the largest and latest EU R&D initiative that's investing a total of almost €80 billion ($86.9 billion) from 2014 to 2020 to stimulate technology transfer.